Background {#Sec1}
==========

Spinal bone metastases represent the most frequent site of skeletal metastases \[[@CR1]\]. The effects of bone metastases are a major concern in everyday clinical practice and result in pain at rest and during activity, limitations in daily life, lower performance ability, risk of pathological fractures and neurologic deficits \[[@CR2]\], with a significant reduction in the patients' quality of life (QoL). Radiotherapy (RT) is the most common treatment option of bone metastases in advanced tumor disease \[[@CR3]\]. The aim of therapy hereby is to reduce pain, to improve the functionality, and to prevent complications, for example compression of the spinal cord and pathological fractures. Pathologic fractures occurred in 39 % of patients with breast cancer, in 22 % of patients with prostate cancer, and in 22 % of patients with bone metastases from lung cancer or other solid tumors during 12, 15, and 21 months of follow up, respectively \[[@CR4], [@CR5]\]. Consequently, pathologic fractures are a significant clinical concern in these patient populations, and preventing or delaying fractures is an important treatment objective. In previous retrospective studies among American and Japanese populations, the incidence of pathologic fractures in the vertebral column is estimated to range at 10 % \[[@CR6], [@CR7]\]. Clinical care of unstable metastases in many centers often includes patient immobilization either by means of an orthopedic thoracic corset or by confining the patient to bed in order to prevent pathological fractures, which further decreases patients\` QoL. Accordingly the incidence of pathological fractures after RT in patients with spinal bone metastases while wearing an orthopedic corset is still unknown. The aim of this retrospective analysis was to evaluate the incidence of pathological fractures after RT in patients with and without orthopedic corsets and to assess prognostic factors for incidence of pathological fractures in patients with spinal bone metastases.

Methods {#Sec2}
=======

A cohort of 915 patients, was treated by RT for osteolytic metastases of the vertebral column due to histologically diagnosed solid tumors at the University Clinic of Heidelberg in the period from January 2000 until January 2012. All patients were examined using computed tomography scans (CT) in this retrospective analysis. Inclusion criteria were an osteolytic phenotype, location in the thoracic or lumbar spine and a minimum duration of follow-up treatment of 6 months. A total of 2.195 bone lesions in the thoracic and lumbar spine were identified. Bone metastases diagnoses were verified by CT. The patient data were taken from the Heidelberg NCT Cancer Registry and are summarized in Table [1](#Tab1){ref-type="table"}. Performance status was expressed using the Karnofsky Performance Score (KPS) \[[@CR8]\]. The specifications for an unstable vertebral body were tumor occupancy of more than 60 % of the vertebral body, and pedicle destruction \[[@CR9]\]. Patients with an orthopedic corset used a thoraco-lumbo-sacral orthosis (TLSO) brace. The prescribed corset was prophylactically with no relation to existence of a pathological fracture. The pathological fractures were evaluated in the irradiated spinal region. New diagnosed fractures were analyzed prior to RT and 6 months after RT. This study was approved by the Heidelberg Ethics Committee on 22 October 2012 (nr S- 513/2012).Table 1Patient characteristicsCorset groupNo corset groupAll*n*%*n*%*n*%Age (mean, SD)63.2 (+/− 11.4)62.2 (+/−10.8)62.7 (+/−11.1)Gendermale23653.425353.548953.4female20646.622046.542646.6KPS\<=7020446.221846.142246.1\>7023853.825553.949353.9Primary siteNSCLC10122.920643.542546.5Breast21949.67415.617519.1Kidney7116.18818.615917.4Melanoma153.4265.5414.5Prostate40.9132.8171.9Other5111.510522.29810.6LocalizationThoracic28464.327959.056361.5Lumbar15835.719441.035238.5Chemotherapyyes24254.726055.150254.9no20045.321244.941245.1Stability before RTstable14031.732067.746050.3unstable30268.315332.345549.7Stability after 3 monthsstable15239.827979.044959.2unstable23060.27921.030940.8Stability after 6 monthsstable16545.131185.247665.1unstable20154.95414.825534.9Bisphosphonatesyes35179.429662.664770.7no9120.617737.426829.3Distant metastasesBrain5011.37716.312713.9Lung7416.711825.019221.0Liver7015.811624.518620.3Skin112.5255.3363.9Number of metastasessolitary18942.822848.241745.6multiple25357.224551.849854.4*SD* Standard deviation; *KPS* Karnofsky performance score; *RT* Radiotherapy

Statistical analysis {#Sec3}
--------------------

The empirical distribution of continuous variables is described by the number of observations, mean and standard deviation; the description of categorical variables includes the number and percentage of patients belonging to the relevant categories. We estimated number of observations of pathological fractures before and 6 months after RT and compared them between groups according to the chi-square test. The univariate log-rank test was used to evaluate the prognostic importance for occurrence of pathological fractures of gender, Karnofsky performance score, non-small cell lung cancer (NSCLC), breast cancer, kidney cancer, localization of metastases, chemotherapy prior to RT, stability prior to RT, stability after 3 months, stability after 6 months, bisphosphonates, and number of bone metastases. Results were reported as *p*-values of the logrank tests. Bivariate analysis was performed to detect factors independently associated with pathological fractures using a Cox regression model. This regression analysis was performed including gender (male), Karnofsky performance score (\<=70), NSCLC (no primary), breast cancer (no primary), kidney cancer (no primary), localization of metastases (thoracic), chemotherapy prior to RT (no chemotherapy), stability prior to RT (unstable), stability after 3 months (unstable), stability after 6 months (unstable), bisphosphonates (no bisphosphonates), and number of bone metastases (solitary metastasis). The results are reported as *p*-values, odds ratios and 95 % confidence intervals (CI). For all analyses, a *p*-value of 0.05 or less was considered significant. All statistical analyses were done using the SAS software version 9.3 (SAS Institute, Cary, NC, USA).

Radiotherapy {#Sec4}
------------

RT was performed in the Department of Radiation Oncology at the Heidelberg University Clinic. After virtual simulation was performed to plan the radiation schedule, RT was carried out over a dorsal photon field of the 6MV energy range. The photon field covered the specific vertebral body affected as well as the ones immediately above and below. The median individual dose in all patients was 3 Gy (range 2--3 Gy), the median total dose 30 Gy (range 20--35 Gy). The individual and total doses were decided separately for each individual patient, depending on histology, the patient's general state of health, the current staging, and the corresponding prognosis.

Results {#Sec5}
=======

The mean follow-up was 6.3 months for both groups. Of all patients, 31.7 % (140 patients) in the corset group and 67.7 % (320 patients) in the no-corset group were classified as stable prior to RT, 79.4 % (*n* = 351) and 62.6 % (*n* = 296) of the corset and no corset group were also treated with bisphosphonates. Considering the number of metastases, 57.2 % (*n* = 253) in the corset group and 51.8 % (*n* = 245) in the no corset group showed multiple metastases. The incidence of unstable metastases was higher in the corseted group (68.3 %) compared to the non-corseted group (32.3 %) prior to RT (*p* \< 0.01). The incidence of pathological fractures prior to RT was 7.4 % in all patients. In the corset group, 6.8 and 8.0 % in no-corset group showed pathological fractures prior to RT, no significant difference between groups was detected (*p* = 0.473). After 6 months, the fracture rate was in total 9.0 % for all patients and correspond 1.6 % new diagnosed fractures. Patients in corset group showed in 8.6 % and in no-corset group in 9.3 % pathological fractures (correspond 1.8 and 1.3 % new diagnosed fractures) (*p* = 0.709). The thoracic spine showed more fractures significantly (Table [2](#Tab2){ref-type="table"}).Table 2Pathological fractures before and after RTAllCorset groupNo corset group*p*-value*n*%*n*%*n*%between groupsPathological fractureyes687.4306.8388.0before RTno84792.641293.243592.00.473thoracic4261.82273.32052.6lumbar2638.2826.71847.40.081Pathological fractureyes829.0388.6449.3after 6 monthsno83391.040491.442990.70.709thoracic5162.22873.72352.3lumbar3137.81026.32147.70.046Pathological fractures before and 6 months after RT in corset and no corset group

The univariate and bivariate analyses identified no significant prognostic factors for incidence of pathological fractures in both groups (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).Table 3Univariate analysis of prognostic factors for incidence of pathological fracturesFactorCorset groupNo corset group*p*-value*p*-valueGender0.3570.642KPS0.4020.819NSCLC0.1010.184Breast cancer0.4960.091Kidney cancer0.0720.195Localization0.2050.342Chemotherapy0.4540.379Stability before RT0.2680.677Stability after 3 months0.5130.614Stability after 6 months0.2020.402Bisphosphonates0.1830.420Number of metastases0.1450.229Table 4Bivariate analysis of prognostic factors for incidence of pathological fracturesAllCorset groupNo corset groupOR95 % CI*p*-valueOR95 % CI*p*-valueOR95 % CI*p*-valueGender0.7970.503--1.2620.3330.7270.369--1.4340.3580.8620.461--1.6120.642KPS0.8430.535--1.3270.4610.7530.387--1.4650.4030.9300.500--1.7310.819NSCLC0.6040.376--0.9690.0360.5660.285--1.1260.1050.6450.336--1.2370.186Breast cancer0.5620.284--1.1130.0980.7450.318--1.7460.4980.3690.111--1.2250.103Kidney cancer1.0710.595--1.9280.8182.0080.928--4.3450.0760.5340.204--1.3980.202Localization0.9700.607--1.5480.8970.6180.292--1.3080.2081.3510.725--2.5170.343Chemotherapy1.0200.647--1.6090.9311.2950.657--2.5550.4551.3290.704--2.5110.381Stability before RT0.9370.595--1.4740.7770.6470.298--1.4060.2711.1550.586--2.2760.677Stability after 3 months0.9930.594--1.6600.9800.7760.363--1.6600.5141.2660.505--3.1740.614Stability after 6 months0.9390.537--1.6420.8260.5870.256--1.3430.2071.6820.493--5.7400.406Bisphosphonates0.9390.573--1.5380.8030.6060.288--1.2740.1861.3130.676--2.5500.421Number of metastases1.3140.826--2.0900.2491.6890.829--3.4420.1490.6830.365--1.2770.232

Discussion {#Sec6}
==========

Bone metastases are common in patients with advanced malignancies. The spinal column is the most common site of bone metastases. Metastatic vertebral body collapse is one of the major causes of severe back pain and neurologic compromise. Therefore, prevention of pathologic fractures is of clinical importance to maintain patients\` QoL.

Bone metastases from solid tumors can dramatically increase bone resorption, resulting in skeletal complications such as pathologic fractures (10--20 % of patients), spinal cord compression (5 % of patients), hypercalcemia of malignancy (10--15 % of patients), severe bone pain requiring palliative RT, and represent important clinical issues. Fractures may cause severe bone pain, limit mobility, and require surgery and hospitalization for treatment \[[@CR10], [@CR11]\].

Our results showed a pathological fracture rate of 7.4 % in all patients. First, we compared between orthopedic corset and no-corset groups to examine the effectiveness of the corset for prevention of a pathological fracture. The corset group with 6.8 and 8.0 % in the no-corset group did not differ between groups. Additionally, after 6 months no significant difference between groups was detected. In a recent trial, the results showed a pathological fracture rate in 18 % of the vertebral bodies prior to RT. New fractures up to 6 months after therapy were seen in 2 % of all cases \[[@CR12]\]. This 6-months fracture rate was comparable to our results. In previous retrospective studies among American and Japanese populations, the incidence of pathologic fractures in the vertebral column ranges around 10 % \[[@CR6], [@CR7]\] and corresponds to our findings. In a further analysis by Saad et al. \[[@CR13]\], the risk of pathological fracture in association with lung cancer is given at 17 %; this finding, however, was made relative to the entire skeletal system. Pathological fractures are a frequently encountered event; fractures of the vertebral body following RT, on the other hand, are rarely reported. In our results, the thoracic spine showed significant more fractures 6 months after RT. However, 61.5 % of metastases were detected in the thoracic spine. The rib cage and sternum can provide additional structural support, but we could not detect any influence to our results. In the clinical treatment of spinal metastases, many advances have been made in the ability to determine both the size and location of vertebral lesions \[[@CR14], [@CR15]\]. Elevated risk of pathologic vertebral body fracture may not, by itself, justify prophylactic stabilization, as many fractured vertebrae are stable or fractured in a manner that does not compromise the spinal canal \[[@CR2]\]. Increased tumor size, lower BMD, increased load, and pedicle involvement elevate the risk of burst fracture prior to endplate failure \[[@CR15]\]. The study by Taneichi et al. \[[@CR9]\] defines the risk factors for fractures of the vertebral bodies caused by osteolytic metastases and rates the estimated fractures according to different types of metastatic involvement, establishing criteria for assessing the risk of vertebral-body fractures. The risk factors for vertebral-body fractures in the thoracic region (T1-T10) are the tumor size and the degree of destruction of the costovertebral joint; in the thoracolumbar and lumbar region (T10-L5), it is the tumor size and degree of pedicle destruction that are the main factors \[[@CR16]\]. Therefore, Taneichi et al. \[[@CR9]\] conducted radiographic analyses of patients with metastatic spinal tumors and concluded that destruction of the costovertebral joint was one of the major risk factors of vertebral collapse in the thoracic and lumbar spine. Certainly, there are multiple scoring systems to assess spinal instability in the literature \[[@CR17], [@CR18]\]. We used the Taneichi Score because of the practicability and easy appliance in the clinical practice. As a main concern, this scoring system constitutes a simple method for classifying osteolytic metastases in vertebral bodies as „stable"or „unstable"by definition of risk factors such as tumor size and the degree of costovertebral joint destruction for the thoracic region (Th 1 to 10) and tumor size and the degree of pedicle destruction for the lumbar region (Th 11 to L5), which is why this score is employed in this evaluation. Reductions in fracture risk following bisphosphonate treatment are also frequently disproportionate to changes in bone density \[[@CR19], [@CR20]\]. Bisphosphonates were found to reduce the overall risk of skeletal complications by 14 % and to reduce the incidence of fractures by 28 to 37 % \[[@CR21]\]. According to our data, both groups had a high bisphosphonates rate so that this bias was negligible small. Recently, however, zoledronic acid has demonstrated efficacy in the management of bone pain and prevention of SREs, including pathologic fractures \[[@CR19]\]. However, bisphosphonate therapy was not a prognostic factor for pathological fractures according to our results.

Pathological fractures play a major role in everyday clinical practice. Common clinical care of unstable metastases or existing fractures often includes patient immobilization either by means of an orthopedic corset or by confining the patient to bed in order to prevent pathological fractures, which further decreases patients\` quality-of-life (QoL). Secondly, the pain, which can be severe, is mechanical in origin, and frequently the patient is only comfortable when lying still. However, no data regarding the appearance of pathological fractures by wearing a corset exist so far. According to our results, patients without an orthopedic corset did not have an increased risk of pathological fractures after RT. In both groups unstable metastases were detected, while the number in the corset group was significantly higher. In our opinion, wearing a corset also maintains some disadvantages in palliative patients: atrophy of the paravertebral musculature, limitation in mobility and reduction of the QoL. The importance of the corset in stability-endangering metastases was discussed up to now controversially, whether thereby fractures can be avoided. The vertical pressure load on the vertebral body also continues with corset, only axial movements can be decreased. Some prognostic factors as mentioned above are already known, our analysis could not identify prognostic factors for both groups. Only no NSCLC as primary site in all patients was significant, however, this result was affected due to a large number of evaluated NSCLC patients. Therefore, this point cannot be derived a factor. The main limitation of this study was the higher incidence of unstable vertebral bodies in patients in the corseted group (68.3 %) compared to the non-corseted group (32.3 %). Further limitations were the variety of primary tumors and the exclusion of patients presenting with cervical spine metastases. Among the strengths of our analysis were the large cohort and the very pertinent clinical question for patients with spinal bone metastases. This was, to our knowledge, the very first analysis to determine if a corset had any utility in preventing the incidence of pathologic fractures after routine radiotherapy.

Conclusion {#Sec7}
==========

In this analysis, we could show for the first time in more than 900 patients, that by omission of corsets the fracture rate was not increased. Importantly, the incidence of a pathological fracture after RT was seldom. Large randomized trials are necessary to confirm these findings.
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